The technology employed in Theravision™ is ultrasound, advanced technology for thermal therapy. The technical properties of ultrasound create ability to optimize directionality and tumor conformance. Key benefits of Theravision™ include: technology to precisely shape and conform volume to treatment target; discretionary avoidance of nearby sensitive structures; eliminate undertreatment or complications.
Primary Application Area: Medical Devices
Technology Development Status: Ready to Market
FIGURES OF MERIT
Value Proposition: AMS has developed Theravision™, a proprietary, image-guided, minimally invasive precision ultrasound ablation therapy system capable of providing superior treatment for many types of cancer, consisting of a reusable control and monitoring console, and single use catheter or needle based ultrasound ablation applicators, allowing for a "minimally invasive" treatment procedure, which in many cases can be delivered on an outpatient basis. Real time 3-D tracking steers the applicators to the tumor site, and the direction, volume and shape of energy (conforming to the tumor) are controlled on a dynamic basis, providing optimal treatment of the tumor, while minimizing damage to surrounding tissue. It can deliver patient-specific customized treatments, improving clinical outcomes and safety. Theravision™ delivers precise, conformal and rapid volumetric ablation in a sophisticated, yet physician-friendly system.
Organization Type: Corporation
Showcase Booth #: 35M
GOVT/EXTERNAL FUNDING SOURCES
Vetted Programs/Awards: AMS was featured in the NCI Bypass Budget, with a significant descriptive account of our technology, (www.cancer.gov/PublishedContent/Files/aboutnci/budget_planning_leg/plan-archives/nci_plan_2013.pdf.) Page 62.
SBIR/STTR Awards: NATIONAL CANCER INSTITUTE 1,287,961.00 08/01/2014-07/31/2016
NATIONAL INSTITUTE OF DIABETES 760,259.00 09/25/2015-08/31/2016
AND DIGESTIVE AND KIDNEY DISEASES
NATIONAL CANCER INSTITUTE 3,150,000.00 08/01/2008-07/31/2013
NATIONAL CANCER INSTITUTE 3,121,754.00 06/01/2009-05/31/2014
External Funding to Date: AMS has conducted contracted product development for large medical device companies. There are no angel or VC funds. AMS is seeking funding to conduct disease site-specific clinical studies.